Carnitine palmitoyltransferase 1C deficiency causes motor impairment and hypoactivity

Behavioural Brain Research

Volumn 256, Issue , 2013, Pages 291-297

  Carrasco, Patricia ^a,b,f   Jacas, Jordi ^a   Sahún, Ignasi ^c,d,g   Muley, Helena ^a   Ramírez, Sara ^a   Puisac, Beatriz ^e   Mezquita, Pau ^a   Pié, Juan ^e   Dierssen, Mara ^c,d   Casals, Núria ^a,b  

^a UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^e UNIVERSITY OF ZARAGOZA   (Spain)

^f GOETHE UNIVERSITY   (Germany)

^g UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Ceramide; CPT1C; Locomotor activity; Motor coordination; Muscle strength

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE I; CARNITINE PALMITOYLTRANSFERASE IC; CERAMIDE; SPHINGOSINE; UNCLASSIFIED DRUG; CARNITINE PALMITOYLTRANSFERASE; CPT1B PROTEIN, MOUSE;

AGE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BIRTH; BRAIN METABOLISM; CARNITINE PALMITOYLTRANSFERASE 1C DEFICIENCY; CEREBELLUM; CONTROLLED STUDY; COORDINATION DISORDER; CORPUS STRIATUM; DISEASE COURSE; DISEASE SEVERITY; ENZYME DEFICIENCY; EXPLORATORY BEHAVIOR; HYPOACTIVITY; KNOCKOUT MOUSE; LIPID METABOLISM; MALE; MOTOR CORTEX; MOTOR DYSFUNCTION; MOUSE; MUSCLE WEAKNESS; NEUROLOGIC EXAMINATION; NEUROLOGIC GAIT DISORDER; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSORY SYSTEM; WEANING; ANIMAL; BRAIN; DEFICIENCY; GAIT; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MOTOR ACTIVITY; NEWBORN; PATHOPHYSIOLOGY; PHYSIOLOGY; REFLEX; ROTAROD TEST; WESTERN BLOTTING;

ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; BRAIN; CARNITINE O-PALMITOYLTRANSFERASE; CERAMIDES; DISEASE PROGRESSION; GAIT; MALE; MICE, KNOCKOUT; MOTOR ACTIVITY; MOVEMENT DISORDERS; MUSCLE WEAKNESS; NEUROLOGIC EXAMINATION; REFLEX; ROTAROD PERFORMANCE TEST; SPHINGOSINE;

EID: 84883680991     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.08.004     Document Type: Article

References (21)

1. Price N., van der Leij F., Jackson V., Corstorphine C., Thomson R., Sorensen A., et al. A novel brain-expressed protein related to carnitine palmitoyltransferase I. Genomics 2002, 80:433-442.
2. Wolfgang M.J., Kurama T., Dai Y., Suwa A., Asaumi M., Matsumoto S., et al. The brain-specific carnitine palmitoyltransferase-1c regulates energy homeostasis. Proc Natl Acad Sci U S A 2006, 103:7282-7287.
3. Sierra A.Y., Gratacos E., Carrasco P., Clotet J., Urena J., Serra D., et al. CPT1c is localized in endoplasmic reticulum of neurons and has carnitine palmitoyltransferase activity. J Biol Chem 2008, 283:6878-6885.
4. Bonnefont J.P., Djouadi F., Prip-Buus C., Gobin S., Munnich A., Bastin J. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med 2004, 25:495-520.
5. Carrasco P., Sahun I., McDonald J., Ramirez S., Jacas J., Gratacos E., et al. Ceramide levels regulated by carnitine palmitoyltransferase 1C control dendritic spine maturation and cognition. J Biol Chem 2012, 287:21224-21232.
6. Gao X.F., Chen W., Kong X.P., Xu A.M., Wang Z.G., Sweeney G., et al. Enhanced susceptibility of Cpt1c knockout mice to glucose intolerance induced by a high-fat diet involves elevated hepatic gluconeogenesis and decreased skeletal muscle glucose uptake. Diabetologia 2009, 52:912-920.
7. Gao S., Zhu G., Gao X., Wu D., Carrasco P., Casals N., et al. Important roles of brain-specific carnitine palmitoyltransferase and ceramide metabolism in leptin hypothalamic control of feeding. Proc Natl Acad Sci U S A 2011, 108:9691-9696.
8. Ramirez S., Martins L., Jacas J., Carrasco P., Pozo M., Clotet J., et al. Hypothalamic ceramide levels regulated by CPT1C mediate the orexigenic effect of ghrelin. Diabetes 2013, 62:2329-2337.
9. Rogers D.C., Fisher E.M., Brown S.D., Peters J., Hunter A.J., Martin J.E. Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm Genome 1997, 8:711-713.
10. Costa A.C., Walsh K., Davisson M.T. Motor dysfunction in a mouse model for Down syndrome. Physiol Behav 1999, 68:211-220.
11. Serra D., Casals N., Asins G., Royo T., Ciudad C.J., Hegardt F.G. Regulation of mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme A synthase protein by starvation, fat feeding, and diabetes. Arch Biochem Biophys 1993, 307:40-45.
12. Jáuregui O., Sierra A.Y., Carrasco P., Gratacós E., Hegardt F.G., Casals N. A new LC-ESI-MS/MS method to measure acylcarnitine levels in cultured cells. Anal Chim Acta 2007, 599(1):1-6.
13. Tokutake Y., Onizawa N., Katoh H., Toyoda A., Chohnan S. Coenzyme A and its thioester pools in fasted and fed rat tissues. Biochem Biophys Res Commun 2010, 402:158-162.
14. Ben-David O., Futerman A.H. The role of the ceramide acyl chain length in neurodegeneration: involvement of ceramide synthases. Neuromolecular Med 2010, 12:341-350.
15. Wolfgang M.J., Cha S.H., Millington D.S., Cline G., Shulman G.I., Suwa A., et al. Brain-specific carnitine palmitoyl-transferase-1c: role in CNS fatty acid metabolism, food intake, and body weight. J Neurochem 2008, 105:1550-1559.
16. Reamy A.A., Wolfgang M.J. Carnitine palmitoyltransferase-1c gain-of-function in the brain results in postnatal microencephaly. J Neurochem 2011, 118:388-398.
17. Furuya S., Mitoma J., Makino A., Hirabayashi Y. Ceramide and its interconvertible metabolite sphingosine function as indispensable lipid factors involved in survival and dendritic differentiation of cerebellar Purkinje cells. J Neurochem 1998, 71:366-377.
18. Zhao L., Spassieva S.D., Jucius T.J., Shultz L.D., Shick H.E., Macklin W.B., et al. A deficiency of ceramide biosynthesis causes cerebellar purkinje cell neurodegeneration and lipofuscin accumulation. PLoS Genet 2011, 7:e1002063.
19. Irie F., Hirabayashi Y. Ceramide prevents motoneuronal cell death through inhibition of oxidative signal. Neurosci Res 1999, 35:135-144.
20. Goodman Y., Mattson M.P. Ceramide protects hippocampal neurons against excitotoxic and oxidative insults, and amyloid beta-peptide toxicity. J Neurochem 1996, 66:869-872.
21. van Adel B.A., Tarnopolsky M.A. Metabolic myopathies: update 2009. J Clin Neuromuscul Dis 2009, 10:97-121.